$ANIX

Anixa Biosciences Inc

Anixa Biosciences is a biotechnology company developing cancer therapies and vaccines for unmet needs in oncology. Its therapeutics program centers on lira-cel, a CAR-T cell therapy initially being developed for ovarian cancer by subsidiary Certainty Therapeutics, in collaboration with Moffitt Cancer Center. Its vaccine programs include investigational vaccines targeting breast cancer and ovarian cancer, plus discovery work on potential vaccines for lung, colon and prostate cancers, conducted with Cleveland Clinic. Anixa also maintains limited patent-licensing activities. Anixa’s programs rely on licensed technologies and research collaborations. Its past revenue comes from technology licensing and sales of patented technologies, including litigation settlements; it has not generated revenue from its therapeutic or vaccine programs. It aims to license technologies to pharmaceutical companies for manufacture and commercialization. Anixa is headquartered in San Jose, California, and had four full-time employees as of October 31, 2025.

5
0
0
$40K
—
Titterton Lewis H jr
0%
See all $ANIX insider activity →
Low

Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology

Anixa Biosciences (NASDAQ: ANIX) received a Canadian patent for its ovarian cancer vaccine technology, expanding its international intellectual property protection. The patent, licensed from Cleveland Clinic, covers methods of immunizing against a protein domain linked to ovarian cancer. This complements Anixa's existing U.S. patent and supports its cancer vaccine portfolio, which includes a breast cancer vaccine that recently completed a Phase 1 trial.

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) partners with Curia to develop a stable formulation for its breast cancer vaccine ahead of Phase 2 trials. The vaccine, developed with Cleveland Clinic, showed promising results in Phase 1, with 74% of participants exhibiting immune responses. Curia will optimize the vaccine's stability and scalability for clinical manufacturing.

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

ANIX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ANIX (Anixa Biosciences Inc). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.

Recent ANIX coverage spans financial news, technology and insider activity.

In the last 30 days, ANIX insiders filed 2 SEC Form 4 transactions — 2 purchases ($40K) and no sales. The most active reporter was Titterton Lewis H jr with 1 filing.

What's driving ANIX

AlphAI scores every news story that mentions ANIX with an AI model for sentiment and relevance, and aggregates insider trades from Anixa Biosciences Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ANIX

Score

Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology

Anixa Biosciences (NASDAQ: ANIX) received a Canadian patent for its ovarian cancer vaccine technology, expanding its international intellectual property protection. The patent, licensed from Cleveland Clinic, covers methods of immunizing against a protein domain linked to ovarian cancer. This complements Anixa's existing U.S. patent and supports its cancer vaccine portfolio, which includes a breast cancer vaccine that recently completed a Phase 1 trial.

$ANIXMedContract· customer

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) partners with Curia to develop a stable formulation for its breast cancer vaccine ahead of Phase 2 trials. The vaccine, developed with Cleveland Clinic, showed promising results in Phase 1, with 74% of participants exhibiting immune responses. Curia will optimize the vaccine's stability and scalability for clinical manufacturing.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.

$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

Related tickers